Beckman Coulter can stand "toe to toe" with rivals
This article was originally published in Clinica
Executive Summary
Beckman Coulter "now has enough size to stand toe-to-toe with anybody" among the major diagnostic instrument manufacturers, says Jay Steffenhagen, the company's vice-president for corporate strategic planning and business development. He was recounting the strategic value of the five acquisitions made by the company during 1996 and 1997 at the recent UBS Warburg Global Life Sciences conference in New York.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.